

LABORATORY CORP OF AMERICA HOLDINGS

Form 3

January 08, 2016

**FORM 3****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0104Expires: January 31,  
2005Estimated average  
burden hours per  
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Keller Deborah L

(Last) (First) (Middle)

210 CARNEGIE CENTER

(Street)

PRINCETON, NJ 08541

(City) (State) (Zip)

2. Date of Event Requiring  
Statement(Month/Day/Year)  
01/01/2016

3. Issuer Name and Ticker or Trading Symbol

LABORATORY CORP OF AMERICA HOLDINGS  
[LH]4. Relationship of Reporting  
Person(s) to Issuer5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

☐ Director    ☐ 10% Owner  
☒ Officer    ☐ Other  
 (give title below) (specify below)  
 CEO, Covance Drug  
 Development

6. Individual or Joint/Group  
 Filing(Check Applicable Line)  
☒ Form filed by One Reporting  
 Person  
☐ Form filed by More than One  
 Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)

3. Ownership  
 Form:  
 Direct (D)  
 or Indirect  
 (I)  
 (Instr. 5)

4. Nature of Indirect Beneficial  
 Ownership  
 (Instr. 5)

Common Stock

11,412

D    A

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
 information contained in this form are not  
 required to respond unless the form displays a  
 currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)

2. Date Exercisable and  
 Expiration Date  
 (Month/Day/Year)

3. Title and Amount of  
 Securities Underlying  
 Derivative Security  
 (Instr. 4)  
 Title

4. Conversion  
 or Exercise  
 Price of  
 Derivative  
 Security

5. Ownership  
 Form of  
 Derivative  
 Security:  
 Direct (D)

6. Nature of Indirect  
 Beneficial Ownership  
 (Instr. 5)

# Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Restricted Stock Unit	Â (1)	Â (1)	Common Stock	3,660	\$ 0 (2)	D	Â
Restricted Stock Unit	Â (3)	Â (3)	Common Stock	23,420	\$ 0 (2)	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Keller Deborah L 210 CARNEGIE CENTER PRINCETON,Â NJÂ 08541	Â	Â	Â CEO, Covance Drug Development	Â

## Signatures

/s/ F. Samuel Eberts III, Attorney-in-Fact for Deborah L.  
Keller

01/08/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Restricted Stock Units vest in three equal annual installments beginning on 3/11/16.

(2) Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

(3) The Restricted Stock Units vest in two equal annual installments beginning on 3/11/16.

Â

### Remarks:

ExhibitÂ 24Â -Â PowerÂ ofÂ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.